Clinical Trials Browser

Phase 2/3 × Atrasentan × Genitourinary × Clear all

NCT00127478 2007-11-29

A Long Term Safety Study With Atrasentan

Phase 2/3 Completed

Adenocarcinoma, Prostatic Neoplasms